Akeso's Innovative Approach to Pancreatic Cancer: First Patient Dosed in Phase II Study Akeso Inc. has announced a significant milestone in cancer research with the first patient dosed in a Phase II study for advanced pancreatic cancer using a unique antibody fusion protein.

Akeso's Innovative Approach to Pancreatic Cancer: First Patient Dosed in Phase II Study #Hong_Kong #Cancer_Research #Akeso #AK130